HOUSTON — Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, was honored with the Emil Freireich Distinguished Pioneer Award from the Society of Hematologic Oncology (SOHO) during the Eleventh SOHO Annual Meeting in Houston, Texas.
The award is the society’s “most prestigious award” and “serves to honor those that have been pioneers in their work and made a notable impact worthy of high regard and recognition by their peers,” according to SOHO.
Dr. Kantarjian, who has authored over 2,000 peer-reviewed publications, focuses on translational-clinical developmental therapeutics in leukemia. His research and collaborations were the basis for the US Food and Drug Administration approvals of over 20 drugs to treat leukemia, according to his biography from the MD Anderson Cancer Center.
In addition to his roles as Professor and Chair in the Department of Leukemia, Dr. Kantarjian also serves as Associate Vice President for Global Academic Programs and is the Samsung Distinguished University Chair in Cancer Medicine at the MD Anderson Cancer Center.
Dr. Kantarjian is an active SOHO member, serving as Secretary on the SOHO Board of Directors, and as Chair of its Steering Committee and Scientific Committee. He has served the society for 10 years.
The award is named for the named for the late Emil Freireich, MD, who was a founding member of SOHO in 2012 and was elected in 2013 as SOHO’s first president. His “direction in creating the first worldwide society dedicated to hematologic oncology was integral to the mission of SOHO,” according to SOHO.